The bill amends the Controlled Substances Act to add fentanyl, any analogue of fentanyl, and 'counterfeit fentanyl or methamphetamine substances' to an existing criminal prohibition. It also provides a statutory definition of 'counterfeit fentanyl or methamphetamine substance' as a product that both contains fentanyl, a fentanyl analogue, or methamphetamine and is marketed or bears the mark or likeness of another product.
Separately, the bill directs the Drug Enforcement Administration to produce an operational and response plan within 180 days focused on investigating, seizing, and educating about counterfeit pills, and it requires the Attorney General (in consultation with DEA and ONDCP) to provide Congress yearly reports with specified seizure, charge, conviction, geographic, and substance breakdowns — with narrow exceptions for sealed indictments or active investigations. The statute puts a distinct federal focus on pill-form counterfeit substances and on measuring both enforcement activity and prevention campaigns.
At a Glance
What It Does
The bill inserts 'fentanyl, an analogue of fentanyl, or a counterfeit substance' into 21 U.S.C. 843(d)(2), defines 'counterfeit fentanyl or methamphetamine substance,' requires the DEA to issue an operational and response plan within 180 days, and mandates annual DOJ reports to Congress with detailed seizure, charge, and conviction data, especially for pill-form counterfeit substances.
Who It Affects
Federal law enforcement (DEA investigators, DOJ prosecutors, forensic laboratories) who investigate and process counterfeit pill cases; the Office of National Drug Control Policy for prevention coordination; and public-awareness campaign operators whose materials will be audited and potentially reshaped.
Why It Matters
The bill creates a statutory hook targeting counterfeit pills containing fentanyl or methamphetamine, elevates collection of pill-specific enforcement data, and compels the DEA to formalize a coordinated operational response — changing how federal agencies track and prioritize counterfeit-pill investigations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a two-part approach: tighten the criminal code's language to squarely capture counterfeit pill threats, and compel agencies to plan and report. Its definition ties illegal status to both composition (contains fentanyl, a fentanyl analogue, or methamphetamine) and misbranding (marketed or bearing another product's identifying mark).
That combination aims to single out disguised, pill-form substances that mimic legitimate medicines or branded products.
On operations, the DEA must deliver an 'operation and response plan' within 180 days. The statute lists three discrete plan elements: strategies to enable federal investigations and seizures; specific steps to expand education and prevention — with an express nod to evaluating current initiatives like Operation Engage — and tailoring to youth and teens; and an audit of existing campaigns, including 'One Pill Can Kill,' to identify ways to improve messaging and targeting.
The plan requirement is implementation-focused rather than merely advisory; it forces the DEA to map investigative tools, interagency roles, and prevention tactics.For oversight, the Attorney General — consulting DEA and ONDCP — must submit the first report within a year and then annually. The report is granular: aggregate seizure counts, pill-form breakdowns, substance composition in pill seizures, where and when seizures occurred, charging data tied to specific CSA sections (subject to narrow nondisclosure for sealed indictments or to protect active investigations), and conviction/sentencing outcomes.
The reporting mandate is designed to create a longitudinal, evidence-based record of federal activity against counterfeit pills, enabling Congress to see trends in supply, prosecution, and campaign effectiveness.Although the bill centers pill-form counterfeit substances, its mechanics implicate laboratory workflows, evidence standards, and interagency coordination. Labs will need to classify seized items by form and chemical content; prosecutors will need to adapt charging decisions to the statutory definition; and prevention program managers can expect formal review and potential redirection of messaging based on the mandated audit and effectiveness assessment.
The Five Things You Need to Know
The bill's statutory definition requires two things: the seized item must contain fentanyl (or a fentanyl analogue) or methamphetamine, and it must be marketed or falsely bear another product's identifying mark — both elements are necessary.
Section 3 amends 21 U.S.C. 843(d)(2) by inserting the phrase 'fentanyl, an analogue of fentanyl, or a counterfeit substance' immediately after 'methamphetamine,' expanding the list of named targets in that provision.
The DEA must issue an operation and response plan within 180 days of enactment that includes strategies for seizures and investigations, education/prevention measures (with focus on youth), and an audit of existing campaigns like 'One Pill Can Kill.', The Attorney General must deliver the first report to Congress within one year and then annually, and the report must include pill-form breakdowns, substance composition data, geographic and temporal seizure data, prosecution/conviction statistics, and details of prevention measures.
Reporting exclusions are explicit: the DOJ may omit data that would unseal an indictment or would undermine ongoing investigations or charges, creating a statutory carve-out for confidentiality tied to prosecutorial and investigative interests.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the statute the public name 'Stop Pills That Kill Act.' This is a caption-only provision that has no substantive legal effect but signals Congress' focus for later implementation and oversight activities.
Definition of 'counterfeit fentanyl or methamphetamine substance'
Establishes a two-element statutory definition: (1) chemical content (contains fentanyl, any analogue of fentanyl, or methamphetamine) and (2) deceptive presentation (marketed, sold, or falsely bears the trademark/name/likeness of another product). Practically, prosecutors will need to prove both the chemical composition and the deceptive branding to rely on this label; defense strategies may therefore challenge either element. The definition narrows focus to substances that both are chemically dangerous and are meant to deceive by imitating other products, which affects evidentiary needs at seizure and charging stages.
Amendment to Controlled Substances Act — prohibited acts
Modifies the lead-in to 21 U.S.C. 843(d)(2) by inserting 'fentanyl, an analogue of fentanyl, or a counterfeit substance' after 'methamphetamine.' Though terse, this edit broadens the statutory prohibition that follows, bringing fentanyl and counterfeit substances explicitly within the referenced criminal framework. The drafting choice — inserting a phrase in the lead-in rather than creating a standalone subsection — may affect statutory interpretation and how courts read the scope of the existing prohibition's subsections.
DEA operation and response plan (180-day deadline)
Directs the DEA Administrator to design and implement a coordinated operational plan within 180 days for counterfeit fentanyl or methamphetamine substances. The plan must both bolster investigative/seizure capabilities and evaluate prevention outreach, including a required audit of campaigns such as 'One Pill Can Kill' and assessment of Operation Engage. For practitioners, this provision signals impending formal guidance from DEA on operational priorities, evidence collection standards, interagency roles, and youth-targeted outreach strategies.
Annual DOJ report to Congress: seizures, charges, convictions, and prevention
Requires the Attorney General, in consultation with DEA and ONDCP, to submit an annual report beginning within one year of enactment. The statute prescribes specific data elements: aggregate seizures, pill-form counts, substance composition breakdowns for pill seizures, seizure locations/timing, charges filed under particular CSA provisions linked to counterfeit pills, conviction and sentencing outcomes, and descriptions of prevention measures. The section also establishes explicit nondisclosure exceptions when disclosure would unseal an indictment or harm investigations, creating a statutory balance between transparency and prosecutorial confidentiality.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal prosecutors and DOJ leadership — They gain a statutory definition and mandated data that can support targeted charging strategies and resource requests, helping to justify organized prosecutions against counterfeit-pill networks.
- DEA and federal investigators — The operational-plan mandate gives DEA authority to centralize tactics, prioritize seizures of pill-form counterfeit substances, and coordinate cross-jurisdictional investigations with clearer mission parameters.
- Public-health and prevention officials (ONDCP and campaign operators) — The required audit and effectiveness review offers evidence to redesign messaging and allocate prevention dollars toward youth-targeted interventions informed by seizure and composition data.
- Congress and oversight bodies — The annual, itemized reports provide lawmakers with consistent metrics to evaluate federal response trends, resource needs, and the impact of prevention campaigns over time.
- Communities and families affected by counterfeit pills — Better data and a coordinated federal plan can improve situational awareness and, if prevention efforts are retooled effectively, reduce exposure of youth to deceptively branded lethal pills.
Who Bears the Cost
- DEA and DOJ — Must absorb the operational and administrative costs of producing a 180-day plan and recurring detailed annual reports, as well as redirect investigative resources toward pill-specific interdiction and coordination.
- Forensic and public-health laboratories — Face increased laboratory testing, classification, and reporting duties to produce the detailed substance-composition and pill-form breakdowns the statute requires.
- Prevention campaign operators and contractors — Will undergo statutory audits and may need to alter campaigns, invest in new evaluation metrics, or defend existing approaches to meet federal scrutiny.
- State and local law enforcement partners — May shoulder additional workload for evidence collection, reporting to federal partners, and participating in joint operations without dedicated new funding.
- Defendants and defense counsel — Broader statutory hooks and enhanced data-driven prosecutions could increase investigations and charges, particularly for distribution networks producing or shipping counterfeit pills.
Key Issues
The Core Tension
The statute balances a push for stronger supply-side enforcement and clearer prosecutorial tools against the practical limits of proving both chemical composition and deceptive branding, and against the question of whether criminal-law emphasis (seizures and prosecutions) will reduce deaths as effectively as investments in harm reduction and treatment; it forces a choice between prioritizing interdiction and investing in public-health responses without prescribing the latter.
The bill's definition ties criminal labeling to both chemical composition and deceptive branding. That dual requirement narrows the caption 'counterfeit' to items that are both chemically dangerous and intentionally presented as another product, but proving both elements will increase evidentiary burdens on prosecutors and raise questions about what constitutes 'marketing' or an 'identifying mark' in street-distributed pills.
Conversely, the requirement could leave out dangerous but plainly unlabeled fentanyl-containing objects that do not imitate branded products.
Operationally and financially, the statute mandates concrete deliverables — a 180-day DEA plan and annual reports with granular lab and prosecution data. Federal and forensic lab capacity is already strained in many jurisdictions; increased testing and standardized reporting will require coordination, funding, and potentially new interagency data systems.
The bill allows DOJ to withhold data that would unseal indictments or compromise investigations, which protects prosecutorial strategy but also reduces transparency for oversight and independent public-health analysis. Finally, the bill emphasizes interdiction and prevention messaging focused on youth and pills; it does not create new harm-reduction tools (for example, expanded naloxone distribution or safe-use sites), so outcomes will depend on whether agencies pair enforcement with effective, evidence-based public-health interventions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.